|
An Open Label Study of a Peptide Vaccine in Patients with Stage IIb or IIIa Non-Small Cell Lung Cancer Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, trips or professional assistance with a real medical doctor. We aren't docs. Always confer with your doctor about An Open Label Study of a Peptide Vaccine in Patients with Stage IIb or IIIa Non-Small Cell Lung Cancer conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. An Open Label Study of a Peptide Vaccine in Patients with Stage IIb or IIIa Non-Small Cell Lung Cancer Clinical research trials and An Open Label Study of a Peptide Vaccine in Patients with Stage IIb or IIIa Non-Small Cell Lung Cancer health trials happen in many of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the effectualness of new does drugs. The intention of the studies / projects is to figure out particular human healthcare questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to detect cures for all forms of circumstances, like An Open Label Study of a Peptide Vaccine in Patients with Stage IIb or IIIa Non-Small Cell Lung Cancer. An Open Label Study of a Peptide Vaccine in Patients with Stage IIb or IIIa Non-Small Cell Lung Cancer Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment options before they are available to the general public. Most times the subjects get treatment for free of charge, and occasionally they are paid for their time. Occasionally there is a cost for a An Open Label Study of a Peptide Vaccine in Patients with Stage IIb or IIIa Non-Small Cell Lung Cancer clinical trial. Subjects frequently get the best healthcare possible for their An Open Label Study of a Peptide Vaccine in Patients with Stage IIb or IIIa Non-Small Cell Lung Cancer condition. Hazards are a reality, however, and could include more or frequent mD visits, health risks (possibly life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > An Open Label Study of a Peptide Vaccine in Patients with Stage IIb or IIIa Non-Small Cell Lung Cancer  An Open Label Study of a Peptide Vaccine in Patients with Stage IIb or IIIa Non-Small Cell Lung Cancer
An Open Label Study of a Peptide Vaccine in Patients with Stage IIb or IIIa Non-Small Cell Lung Cancer
For Condition: Carcinoma, Non-Small-Cell Lung,Lung Neoplasm
Status: Completed
Sponsor(s): Epimmune ,
Synopsis: EP2101 is a new cancer vaccine containing 10 different peptide antigens. The vaccine is designed to activate the immune system to develop a response against tumor cells in order to delay or prevent the recurrence of cancer. This study will test the safety and measure the level of immune stimulating capability of EP2101 in patients with Non-Small Cell Lung Cancer.
Details:
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Confirmed diagnosis of Non-Small Cell Lung Cancer, stage IIb or IIIa - At least four weeks following prior standard treatment, with no evidence of disease - Must use adequate birth control Exclusion Criteria: - Prior cancer vaccine therapy or concurrent participation in any other investigational study - A history of HIV, Hepatitis B or C, or any other acute medical condition which may compromise patient safety or the activity of the study vaccine treatment - A history of adverse reactions following administration of any vaccines, or a history of hypersensitivity to any components of the study vaccine - Women who are pregnant, intend to become pregnant, or who are breast feeding
Total Enrollment: 18
Location and Contact Information:
Mary Crowley Medical Research Center
Dallas, Texas, 75246
United States
New York Oncology Hematology
Albany, New York, 12208
United States
University of Washington
Seattle, Washington, 91895
United States
Duke University Medical Center
Durham, North Carolina, 27710
United States
Tyler Cancer Center
Tyler, Texas, 75702
United States
Cancer Centers of Florida
Orlando, Florida, 32806
United States
Cancer Care Northwest
Spokane, Washington, 99218
United States
University of California, Los Angeles
Los Angeles, California, 90095
United States
Additional Information:
Study ID Numbers: EP2101-101;
Study Start Date: January 2003
Record last reviewed: April 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00054899
Other Lung Neoplasm Studies:
1. Phase I Study of LMB-9, a Recombinant Disulfide Stabilized Immunotoxin for Advanced Carcinomas that Express Lewis Y Antigen
2. Depsipeptide to Treat Lung Cancer
3. An Open Label Study of a Peptide Vaccine in Patients with Stage IIb or IIIa Non-Small Cell Lung Cancer
4. Vaccine Therapy with Tumor Specific Mutated RAS Peptides and IL-2 or GM-CSF for Adult Patients with Solid Tumors
5. A Safety and Tolerability Study of Oral TAK-165 Administered to Subjects with Tumors Known to Express HER2
Related Studies:
Other Lung Neoplasm Clinical Trials
Other Texas Clinical Trials
Other Dallas Clinical Trials
An Open Label Study of a Peptide Vaccine in Patients with Stage IIb or IIIa Non-Small Cell Lung Cancer
|
|
|
|
|
|
|
|
